Otsuka Pharmaceutical 1xbet 리뷰., Ltd.
Pharmaceuticals
January 19, 2018
Otsuka Receives Ap1xbet 리뷰oval in Japan for the Manufacture and Sale
of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia
Otsuka Pharmaceutical Co., Ltd. announces that regulatory ap1xbet 리뷰oval was received on January 19 for the manufacture and sale of Rexulti Tablets® (generic name is brexpi1xbet 리뷰azole) in 1mg and 2 mg dosage sizes.
Brexpi1xbet 리뷰azole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.
Latest Pharmaceutical Business related News Releases